Exicure Inc Cash Flow Conversion Efficiency
Exicure Inc cash flow conversion efficiency. Based on the latest financial reports, Exicure Inc (XCUR) has a cash flow conversion efficiency ratio of -0.908x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-887.00K) by net assets ($977.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Exicure Inc (2015–2025)
Cash flow conversion efficiency of Exicure Inc from 2015 to 2025. This chart illustrates how Exicure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View XCUR live share price for real-time trading data and today's change.
Exicure Inc Cash Flow Conversion Ratio Explained
Exicure Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Exicure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Exicure Inc ranked by their cash flow conversion efficiency. Also see XCUR market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oxbridge Re Holdings Ltd
NASDAQ:OXBR
|
-0.014x |
|
Nutritional Growth Solutions Ltd
AU:NGS
|
-0.240x |
|
Pipe Works L. Girakian Profil S.A.
AT:PROFK
|
-0.030x |
|
Fresh Grapes LLC
NYSE MKT:VINE
|
-0.396x |
|
Chiangmai Rimdoi Public Company Limited
BK:CRD
|
0.179x |
|
Indo Oil Perkasa PT
JK:OILS
|
-0.085x |
|
Encres Dubuit SA
PA:ALDUB
|
0.056x |
|
Orange Minerals NL
AU:OMX
|
-0.043x |
Annual Cash Flow Conversion Efficiency for Exicure Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Exicure Inc from 2015 to 2025. Review Exicure Inc (XCUR) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.93 Million | $-8.55 Million | -2.179x | -407.10% |
| 2024-12-31 | $6.77 Million | $-2.91 Million | -0.430x | +87.42% |
| 2023-12-31 | $3.03 Million | $-10.36 Million | -3.417x | -42.99% |
| 2022-12-31 | $14.92 Million | $-35.66 Million | -2.390x | +22.91% |
| 2021-12-31 | $11.23 Million | $-34.82 Million | -3.100x | -385.53% |
| 2020-12-31 | $61.51 Million | $-39.27 Million | -0.638x | -4014.57% |
| 2019-12-31 | $80.75 Million | $1.32 Million | 0.016x | +101.75% |
| 2018-12-31 | $20.95 Million | $-19.49 Million | -0.930x | +6.12% |
| 2017-12-31 | $19.98 Million | $-19.79 Million | -0.991x | +51.98% |
| 2016-12-31 | $2.45 Million | $-5.05 Million | -2.063x | -208.20% |
| 2015-12-31 | $18.23 Million | $-12.20 Million | -0.669x | -- |
About Exicure Inc
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood Ci… Read more